Rx Update: October 2002

Review of Insulin Products

Mary Ross, R.Ph., M.B.A., Barbara Mutnick, R.Ph., M.H.P., Joan Murhammer, R.Ph.
Peer Review Status: Internally Reviewed


There have been a number of new insulin products introduced in the US for the treatment of diabetes. The onset, peak, and duration of action after subcutaneous injection of the newer products as compared to the other available insulin preparations are listed in the table below. The compatibility of the insulin mixes is also shown.

Insulin Type

Brand Name(s)
Onset
(hrs)
Peak
(hrs)
Duration (hrs)
Compatible mixed with
Rapid

Aspart

NovoLog®
0.25
0.75-1.5
3-5
NPH

Lispro

Humulog®
0.25
0.5-1.5
5 or less
Ultralente, NPH
Short Acting

Regular

Novolin R®
Humulin R® Reg/Iletin II Pork®
Velosulin®
0.5-1
2-4
5-7
Lente, Ultralente, NPH
Intermediate Acting

Isophane
(NPH)

NPH/Iletin II Pork®
Novolin N®
Humulin N®
1-3
6-12
24-28
Regular

Lente
(zinc suspension)

Humulin L®
Novolin L®
1-3
6-12
24-28
Regular
Long Acting

Glargine

Lantus®
1
4-5 (blunted)
24
None

Ultralente
(zinc suspension -- extended)

Humulin U®
4-6
16-24
36+
Regular

There are other important aspects to the dosing and administration of the newer insulins. These include:

Title Page